Yes, alemtuzumab (anti-CD52, Campath-1H) is effective for remission induction in patients diagnosed with T-cell prolymphocytic leukemia.
Alemtuzumab can be administered in combination with other chemotherapeutic agents or as mono-therapy.
Response rate to alemtuzumab is more than 90%.
Alemtuzumab therapy is associated with improved survival of T-cell prolymphocytic leukemia patients.
